GTC Biotherapeutics (fka GTCB)

[keitern]

Is a lower cost of GTC AAT vs plasma derived AAT part of the rational for the alpha-1 antitripsin program? Are competing products (inhaled) under development also plasma derived?

From CC:
"Remember that we established high levels of production of this difficult to express protein at 20 grams per liter of milk."

PS: Is there any way to charachterize the probabilities this product has to succeed and the size, length, expense and difficuties of the trials etc.?